The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Tennessee Oncology
Virtual easy-to-access hematology tumor boards: Scaling disease expertise across multiple sites of care across urban and rural Tennessee.
 
Christy L. Schneider
Employment - Tennessee Oncology/OneOncology
 
Kimberly Senneke
Employment - Tennessee Oncology/OneOncology
 
Jonathan Abbas
Speakers' Bureau - Abbvie; Amgen; Pharmacyclics
 
Bertrand Marquess Anz
Employment - Tennessee Oncology
 
Mary-Margaret Allen
No Relationships to Disclose
 
William Bruce Donnellan
No Relationships to Disclose
 
Stephen Anthony Strickland
No Relationships to Disclose
 
Natalie R. Dickson
Employment - Tennessee Oncology
Leadership - OneOncology
Stock and Other Ownership Interests - OneOncology
Consulting or Advisory Role - Abbvie; Blue Cross and Blue Shield of Tennessee; Cigna; Via Oncology
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Flatiron Health; Flatiron Health
 
Katherine Hamilton
No Relationships to Disclose
 
Ian W. Flinn
Consulting or Advisory Role - Abbvie (Inst); BeiGene (Inst); Century Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Hutchison MediPharma (Inst); Innocare (Inst); Kite, a Gilead company (Inst); Myeloid Therapeutics (Inst); Novartis (Inst); Secura Bio (Inst); SERVIER (Inst); TG Therapeutics (Inst); Vincerx Pharma (Inst); Xencor (Inst)
Research Funding - 2seventy bio (Inst); Abbvie (Inst); Acerta Pharma (Inst); Agios (Inst); ArQule (Inst); AstraZeneca (Inst); BeiGene (Inst); Bio-Path Holdings, Inc (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); CALIBR (Inst); Celgene (Inst); City of Hope (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Curis (Inst); Epizyme (Inst); Fate Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Loxo (Inst); Marker Therapeutics (Inst); Merck (Inst); Millennium (Inst); MorphoSys (Inst); Myeloid Therapeutics (Inst); Novartis (Inst); Nurix (Inst); Pfizer (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Rhizen Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Step Pharma (Inst); Tessa Therapeutics (Inst); TG Therapeutics (Inst); Triact Therapeutics (Inst); Trillium Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst)
 
Mindy Hsiao
No Relationships to Disclose
 
Stephen Matthew Schleicher
Employment - Tennessee Oncology
Stock and Other Ownership Interests - OneOncology; Thyme Care
 
Michael Byrne
Consulting or Advisory Role - Abbvie; CTI; Kite, a Gilead Company
Research Funding - Karyopharm Therapeutics